Editorial
Inhibiting C5a/C5aR axis reduces myeloid-derived suppressor cells and enhances PD-1 blockade therapy in lung cancer
Translational Cancer Research
2017;
6
(Suppl 6)
:S944-S948
.
(29 August 2017)
New incriminating evidence against IGF2
Translational Cancer Research
2017;
6
(Suppl 6)
:S949-S952
.
(29 August 2017)
Cancer prevention through better sleeping habits: the circadian clock and hepatocellular cancer
Translational Cancer Research
2017;
6
(Suppl 6)
:S953-S956
.
(29 August 2017)
From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein
Translational Cancer Research
2017;
6
(Suppl 6)
:S957-S960
.
(29 August 2017)
Treatment of elderly patients with glioblastoma: new lessons from CE.6
Translational Cancer Research
2017;
6
(Suppl 6)
:S961-S963
.
(29 August 2017)
The importance of novel molecular biomarker of early stage lung adenocarcinoma
Translational Cancer Research
2017;
6
(Suppl 6)
:S964-S968
.
(29 August 2017)
Synergizing genome editing and cancer immunotherapy
Translational Cancer Research
2017;
6
(Suppl 6)
:S969-S972
.
(29 August 2017)
Postoperative chemoradiotherapy for elderly patients with glioblastoma: worsening frailty or increasing survival?
Translational Cancer Research
2017;
6
(Suppl 6)
:S973-S975
.
(29 August 2017)
REGATTA trial: its achievement and the issues unsolved
Translational Cancer Research
2017;
6
(Suppl 6)
:S976-S978
.
(29 August 2017)
Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma
Translational Cancer Research
2017;
6
(Suppl 6)
:S979-S981
.
(29 August 2017)
Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 6)
:S982-S988
.
(29 August 2017)
Radiotherapy benefits outweigh risks for breast cancer in modern era
Translational Cancer Research
2017;
6
(Suppl 6)
:S989-S992
.
(29 August 2017)
A role for lnc-DILC in liver cancer stem cells
Translational Cancer Research
2017;
6
(Suppl 6)
:S993-S994
.
(29 August 2017)
BRCA1 and BRCA2: two genes, multiple clinical applications
Translational Cancer Research
2017;
6
(Suppl 6)
:S995-S998
.
(29 August 2017)
Vesicular control of metastasis: entrap the “virtuous” and free the “wicked” microRNA
Translational Cancer Research
2017;
6
(Suppl 6)
:S999-S1002
.
(29 August 2017)
CAR-T cell in vivo tracking method using PET scan with the reporter gene and new investigational tracer [18F] FHBG
Translational Cancer Research
2017;
6
(Suppl 6)
:S1003-S1005
.
(29 August 2017)
Post-operative seizure prophylaxis in gliomas
Translational Cancer Research
2017;
6
(Suppl 6)
:S1006-S1009
.
(29 August 2017)
Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1010-S1013
.
(29 August 2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1014-S1017
.
(29 August 2017)
The need for speed: how PD1-blockade only works if T cells are properly activated
Translational Cancer Research
2017;
6
(Suppl 6)
:S1018-S1021
.
(29 August 2017)
Elderly patients with glioblastoma: where are we going?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1022-S1024
.
(29 August 2017)
Would the skyrocketed advances of immune checkpoint inhibitors over chemotherapy be stumbled by the safety issues?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1025-S1026
.
(29 August 2017)
The “eyes” have it?—intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay
Translational Cancer Research
2017;
6
(Suppl 6)
:S1027-S1029
.
(29 August 2017)
Prophylactic cranial irradiation for extensive-stage small-cell lung cancer: an evolving view
Translational Cancer Research
2017;
6
(Suppl 6)
:S1030-S1034
.
(29 August 2017)
Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients
Translational Cancer Research
2017;
6
(Suppl 6)
:S1035-S1039
.
(29 August 2017)
Exosome mediated phenotypic changes in lung cancer pathophysiology
Translational Cancer Research
2017;
6
(Suppl 6)
:S1040-S1042
.
(29 August 2017)
Intensity modulated radiotherapy for head-and-neck cancer: discussing safety of modern radiation techniques
Translational Cancer Research
2017;
6
(Suppl 6)
:S1043-S1048
.
(29 August 2017)
Perspective on long noncoding RNA functionality
Translational Cancer Research
2017;
6
(Suppl 6)
:S1049-S1053
.
(29 August 2017)
Tenascin-C a novel regulator of brain tumor-initiating cells (BTIC) in glioma acts through NOTCH
Translational Cancer Research
2017;
6
(Suppl 6)
:S1054-S1056
.
(29 August 2017)
Tenascin-C induces expression of the Notch ligand Jagged1 to promote glioma growth
Translational Cancer Research
2017;
6
(Suppl 6)
:S1057-S1060
.
(29 August 2017)
Avelumab: a promising PD-L1 inhibitor for lung cancer (with inconvenient infusional reactions)
Translational Cancer Research
2017;
6
(Suppl 6)
:S1061-S1063
.
(29 August 2017)
Back into focus: tumour-associated macrophages and their role in immune checkpoint inhibition
Translational Cancer Research
2017;
6
(Suppl 6)
:S1064-S1065
.
(29 August 2017)
Lymph node metastasis in oesophageal cancer—what we (do not) know?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1066-S1068
.
(29 August 2017)
Brigatinib entering the clinic for ALK rearranged metastatic NSCLC: editorial on a randomized multicenter phase II study with two brigatinib dose regimens
Translational Cancer Research
2017;
6
(Suppl 6)
:S1069-S1073
.
(29 August 2017)
Ceritinib in ROS1-positive non-small cell lung cancer patients: does clinical evidence carry clinical impact?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1074-S1079
.
(29 August 2017)
Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28
Translational Cancer Research
2017;
6
(Suppl 6)
:S1080-S1083
.
(29 August 2017)
Unraveling bio-social hierarchy in cancer collective invasion: symbiosis between leaders and followers
Translational Cancer Research
2017;
6
(Suppl 6)
:S1084-S1087
.
(29 August 2017)
Deferoxamine may enhance 5-aminolevulinic acid-based fluorescence in glioma surgery
Translational Cancer Research
2017;
6
(Suppl 6)
:S1088-S1090
.
(29 August 2017)
Tumor microenvironments of NSCLC are more heterogeneous than you would think—supported by image analysis-based assessment of PD-L1 and tumor-associated immune cell densities
Translational Cancer Research
2017;
6
(Suppl 6)
:S1091-S1097
.
(29 August 2017)
Diffuse intrinsic pontine gliomas: the future of combination therapy with mTORC1/2 inhibitors and radiation
Translational Cancer Research
2017;
6
(Suppl 6)
:S1098-S1100
.
(29 August 2017)
Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes
Translational Cancer Research
2017;
6
(Suppl 6)
:S1101-S1103
.
(29 August 2017)
Epigenetic profiling of tumor infiltrating lymphocytes
Translational Cancer Research
2017;
6
(Suppl 6)
:S1104-S1107
.
(29 August 2017)
Perspective
Progress and impact of clinical phosphoproteomics on precision oncology
Translational Cancer Research
2017;
6
(Suppl 6)
:S1108-S1114
.
(29 August 2017)
Letter to the Editor
What is the significance of TP53 and KRAS mutation for immunotherapy in non-small cell lung cancer?
Translational Cancer Research
2017;
6
(Suppl 6)
:S1115-S1117
.
(29 August 2017)
Detection of clinically relevant T-cell receptors requires tailored approaches, and TCR gene therapy carries inherent risks
Translational Cancer Research
2017;
6
(Suppl 6)
:S1118-S1120
.
(29 August 2017)
Disclosure:
This supplement was published without any sponsorship or funding.
